Taiho Oncology’s TAS-102 shows good results in colorectal cancer

Japanese firm Taiho Oncology, a subsidiary of Otsuka (TYO: 4768), has released positive results from its global Phase III RECOURSE trial on its anticancer drug TAS-102 (trifluridine and tipiracil hydrochloride) in refractory metastatic colorectal cancer (mCRC).

Taiho said the trial met its primary endpoint of demonstrating improvement in overall survival (OS) in patients with refractory mCRC whose disease had progressed after approved standard therapies.

Fabio Benedetti, senior vice president and chief medical officer at Taiho Oncology, said: “We are very pleased by the results from the Phase III RECOURSE trial in refractory mCRC, which support TAS-102 as a potential new treatment option for this patient population. The Taiho Oncology team is preparing for the submission of the NDA and MAA of TAS-102 in the USA and the European Union, respectively.”